Pfizer's revenue has stabilized, and operational efficiency is improving, supporting a "Strong buy" rating with a 6.5% forward dividend yield. The market sentiment in the next few months is likely ...

Investors, in general, have also lost patience. NYSE-listed Pfizer Inc. has corrected by more than 50% from its peak in 2021. NSE-listed Pfizer Ltd, in which the global parent has a 64% stake ...

We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

Feb 24 (Reuters) - Pfizer (PFE.N), opens new tab on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief medical officer, bringing ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Summit Therapeutics and Pfizer on Monday said they will test an experimental Summit immunotherapy with Pfizer’s antibody drug conjugates in trials evaluating two of the sector’s most closely watched ...

The Note 50 series is right around the corner. And we do mean that - there really isn't much waiting left to do for the devices. Infinix has officially started teasing the Note 50 series in ...

Pfizer will no longer develop and commercialize its hemophilia B gene therapy Beqvez across all of its global markets, according to multiple media reports Thursday. In a statement to Nikkei Asia, the ...